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Abstract
Purpose—Hormone receptor positive (HR+) cancers account for most breast cancer diagnoses 
and deaths. Among survivors with HR+ breast cancers, endocrine therapy (ET) reduces 5-year risk 
of recurrence by up to 40%. Observational studies in Medicare and privately-insured survivors 
suggest under-utilization of ET. We sought to characterize ET use in a low-income Medicaid-
insured population in North Carolina.
Methods—Medicaid claims data were matched to state cancer registry records for survivors ages 
18–64 diagnosed with stage 0-II HR+ breast cancer from 2003–2007, eligible for ET, and enrolled 
in Medicaid for at least 12 of 15 months post-diagnosis. We used multivariable logistic regression 
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to model receipt of any ET medication during 15-months post-diagnosis controlling for age, race, 
tumor characteristics, receipt of other treatments, co-morbidity, residence, reason for Medicaid 
eligibility, involvement in the Breast and Cervical Cancer Control Program (BCCCP), and 
diagnosis year.
Results—Of 222 women meeting inclusion criteria, only 50% filled a prescription for ET. 
Involvement in BCCCP and earlier year of diagnoses were associated with significantly higher 
odds of initiating guideline-recommended ET (Adjusted Odds Ratio [AOR] for BCCCP: 3.76, 
95%CI: 1.67–8.48; AOR for 2004 relative to 2007: 2.80, 95%CI: 1.03–7.62; AOR for 2005 
relative to 2007: 2.11, 95%CI: 0.92–4.85).
Conclusions—Results suggest substantial under-utilization of ET in this population. 
Interventions are needed to improve timely receipt of ET and to better support survivors taking ET.
Implications of cancer survivors—Low-income survivors should be counseled on the 
importance of ET and offered support services to promote initiation and long-term adherence.
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Introduction
Over the past 20 years major advances in the treatment of breast cancer have led to earlier 
diagnoses, improved outcomes, and more survivors. Among the estimated 13.7 million 
cancer survivors currently alive in the US, 41% are female breast cancer survivors.[1] As 
treatment options become more sophisticated and prognosis continues to improve, 
supporting ongoing surveillance to address identified gaps in breast cancer survivorship care 
will become increasingly important in further reducing the burden of cancer. From the health 
system perspective, monitoring cancer survivors closely can ensure long-term care needs are 
managed, result in earlier detection of recurrences, improve patient satisfaction, and 
safeguard high quality survivorship care.[2]
An important component of high quality breast cancer survivorship care is long-term use of 
endocrine therapy (ET), the cornerstone of adjuvant treatment to prevent recurrence among 
hormone receptor positive (HR+) (defined as estrogen or progesterone receptor positive) 
breast cancer survivors. HR+ breast cancer is the most common breast cancer phenotype, 
affecting approximately 70% of breast cancer patients, and is the leading cause of breast 
cancer mortality.[3] Five years of treatment with either tamoxifen or an aromatase inhibitor 
(AI) reduces risk of HR+ breast cancer recurrence by 40% and risk of death by one-third.[4] 
Unfortunately, many women do not experience the full benefits of ET due to underuse.[5–9] 
Percentages of HR+ breast cancer survivors who never initiate ET range from 18% in 
women seen at academic medical centers to 36% in low-income women.[10–13] Overall, 
half of women who do initiate ET discontinue or do not take ET as prescribed after five 
years.[7, 6]
Observational studies show the high prevalence of ineffective ET use, document its potential 
impact, and offer insight into how drivers of ET underuse may vary among subgroups. 
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Patient-level factors associated with ET non-initiation in observational studies include 
minority race/ethnicity, competing co-morbidities, more advanced disease,[13, 12] and 
prevalence of reported side effects of ET. Some women report confusion about the hormonal 
nature and actions of tamoxifen, and considerable distress caused by hot flashes, weight 
gain, cessation of menses, and loss of fertility.[14] Similarly, AI have been associated with 
arthralgia, musculoskeletal problems, and gynecologic effects, resulting in underuse of this 
ET medication.[15] Most of the data on ET use come from privately insured or single 
institution or single health plan studies.[16, 17, 13] We need additional data from vulnerable 
populations, such as low-income, Medicaid enrollees, to better understand whether these 
populations are at higher risk for ET underuse and correspondingly worse outcomes. One 
study conducted in New York’s Medicaid population found that only 39% received optimal 
ET including prompt initiation and adherence during the first year post-diagnosis and that 
comorbidity and more advanced disease were associated with failure to initiate.[12] Another 
study conducted in the North Carolina (NC) Medicaid population found that women who 
were older, not married, taking more prescription medications, higher stage, being treated at 
a small hospital, and not receiving chemotherapy or radiation therapy were more likely to 
initiate ET.[11] That study, however, included women with unknown hormone receptor 
status and used Medicaid data from 1998–2002.[11] Providers and decision makers need 
updated data from states like NC (i.e., large, socioeconomically and racially diverse, largely 
rural states with access to care challenges) reflecting more recent trends in ET use in low-
income populations. The purpose of this paper is to update the literature by examining 
initiation of ET among Medicaid-insured HR+ breast cancer survivors diagnosed in 2003–
2007 to understand more clearly how to improve cancer survivorship care in this population.
Methods
Data Sources
Our data include 2003–2007 Medicaid claims and enrollment data for women diagnosed 
with breast cancer in NC in the same years, according to NC Central Cancer Registry 
(NCCCR) records. The database contains paid claims for emergency, inpatient, and 
outpatient services and prescription drug claims, as well as administrative data tracked at the 
patient level longitudinally.
Study Population
We restricted our analyses to women ages 18–64 who had stage 0, I, or II, breast disease 
(Figure 1). We further limited our patient sample to exclude women with stage 0 disease 
who received mastectomy, as ET is not clinically indicated in this group. Eligible women 
were enrolled in Medicaid for at least one month before their initial diagnosis and had no 
evidence of a cancer diagnosis prior to that time according to NCCCR records. To ensure 
that all claims for cancer treatments, hospitalizations, emergency department visits, 
prescriptions, and regular care were recorded in our data, but recognizing that Medicaid 
enrollment can sometimes be transient, we required that women be enrolled in Medicaid for 
at least 12 of the 15 months following the index breast cancer diagnosis, consistent with a 
previously published methodology.[18] We also excluded women who were dually insured 
by Medicare during our study period because we did not have access to Medicare claims; 
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failure to exclude this group would have likely missed relevant claims. Other exclusions 
were based on the same previously published methodology.[18] HR+ status was taken from 
biomarker measures reported in the NCCCR data; we coded positive or elevated estrogen 
and progesterone receptor status as positive.
Dependent Variables
American Society of Clinical Oncology (ASCO) quality metrics for breast cancer 
surveillance for survivors (2006) state that coordination of care, including adjuvant ET for 
women with HR+ disease, should be ensured.[19] National Comprehensive Cancer Network 
(NCCN) guidelines recommend that ET be prescribed for most HR+ patients with stage I-II 
disease and considered for those with HR+, stage 0, ductal carcinoma in situ (DCIS) to 
reduce risk of recurrence and development of a new primary tumor in the contralateral breast 
(Version 3.2013). In accordance with these guidelines, we developed the following binary 
quality of care measure: receipt of any ET (Tamoxifen, Femara/Letrozole, Aromasin/
Exemestane, or Arimidex/Anastroxole) in the 15-month period post-diagnosis, among 
women with HR+ disease. National drug codes used to identify ET in the claims are detailed 
in Supplemental Table 1 (Appendix).
Independent Variables
Based upon published literature, we selected factors associated with quality of survivorship 
care to include in multivariate models.[18] Specifically, independent variables included age 
at diagnosis, race, urban/rural residence at diagnosis, reason for Medicaid eligibility, 
involvement in the Breast and Cervical Cancer Control Program (BCCCP), year of 
diagnosis, co-morbidities, stage at diagnosis, and receipt of breast cancer treatments other 
than ET. We used Medicaid race/ethnicity information, when available, because it is based 
on Social Security information; when it was not available, we used NCCCR race/ethnicity. 
County codes of patient’s residence at diagnosis were used to assign rural or urban 
categories, as determined from the 2003 US Department of Agriculture Economic Research 
Service. We included indicators for ever being classified as blind or disabled for Medicaid 
eligibility and ever being enrolled in BCCCP. Diagnosis year was recorded based upon 
NCCCR data.
Clinical independent variables included presence of co-morbid conditions and cancer stage 
at diagnosis. Presence of co-morbid conditions was determined using the National Cancer 
Institute (NCI) combined index with modification as described elsewhere.[18] Stage at 
diagnosis (stage 0, stage I, and stage II) was derived from the 6th edition American Joint 
Committee on Cancer (AJCC) grouping. Surveillance, Epidemiology and End Results 
(SEER) summary stage was used for the remaining patients when AJCC was not available. 
If neither AJCC nor summary stage were available, we used Tumor, Node, and Metastasis 
(TNM) information to classify into stages. Therapeutic characteristics included receipt of 
breast cancer surgery, radiation therapy, and chemotherapy, which were identified using 
relevant diagnostic and procedural codes, following previously published methodology.[18
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We used descriptive statistics and bivariate analyses to explore distributions of all variables 
and to characterize the study population. Multivariable logistic regression was used to 
examine initiation of ET as a function of all independent variables. We tested the 
specification and functional form of variables such as age, co-morbidity, and year of 
diagnosis and ultimately used the continuous form of age and co-morbidity and categorical 
specifications of year of diagnosis based upon model fit statistics. We considered and tested 
several interaction terms of interest, but due to lack of improvement of model fit and 
considering our relatively small sample size, we elected not to include interaction terms in 
final model estimations. All statistical analyses were conducted using STATA (Stata 12; 
StataCorp, College Station, TX).
We also conducted a secondary analysis restricting the sample to only include women who 
received primary therapy within 15 months of diagnosis (n=147) and examining ET use in 
the next 15 months post-primary therapy completion, because many women do not begin ET 
until after primary treatment (surgery, radiation therapy, and/or chemotherapy) is complete.
Results
Of 1,264 women with stage 0-II or unstaged breast cancer enrolled in Medicaid in the initial 
sample, 222 met inclusion criteria and were included in our final primary analysis. Of these, 
the mean age was 49 years, 47% were white, the majority (67%) lived in urban versus rural 
areas, most women were stage 1 (57%), and 21% participated in BCCCP. More than half of 
our sample received mastectomy (52%), and 26% of our sample received breast conserving 
surgery (BCS), leaving 22% who received no surgical procedure at all during the 15 month 
study period, the majority of whom had stage I or II disease (80%). Only half (50%) had a 
pharmacy claim for ET within 15 months of diagnosis, suggesting significant failure to 
initiate in this population. Among women receiving adjuvant ET (n=111), tamoxifen was the 
most commonly used ET medication (57%), anastrozole was the most commonly used AI 
(50% of AI users), and 7% of women switched among types of ET prescriptions during our 
study period. The mean time to first ET prescription fill was 267 days post-diagnosis. In 
general, as expected, women filling tamoxifen prescriptions were younger than women 
filling AI prescriptions (p<0.001)
In bivariate analyses (Table 1), women who received guideline-recommended ET were more 
likely to have had any surgery (85% versus 71%, p<0.01), more likely to have received 
radiation therapy (67% versus 50% of those who did not get ET, p=0.01) and more likely to 
have been enrolled in BCCCP (31% compared to 12%, p<0.001). Women who did not 
receive any primary therapy (surgery, radiation therapy, and/or chemotherapy) were much 
less likely to receive ET (p<0.004).
Table 2 presents results from the multivariable logistic regression for receipt of ET at any 
time during the 15-month period post-diagnosis among all women with HR+ breast cancer. 
Participation in BCCCP was a highly significant predictor of ET initiation (adjusted odds 
ratio (AOR): 3.76; 95% CI: 1.67–8.48; p<0.01). In addition, earlier year of diagnosis (2004 
or 2005) was associated with higher odds of ET initiation, compared to 2007 (2004 AOR: 
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2.80; 95% CI: 1.03–7.62; p<0.05; 2005 AOR: 2.11, 95% CI: 0.92–4.85; p<0.10). Black 
women had lower odds of ET initiation (AOR: 0.84), but this effect was not statistically 
significant.
Our secondary analysis limited to the women receiving primary therapy during the first 15 
months post-diagnosis (n=147) indicated that 72% of women initiated ET during the 15 
months after primary treatment completion (results not shown).
Discussion
In this study, we sought to describe patterns of ET initiation among low-income, Medicaid-
insured women diagnosed with HR+ breast cancer. ET is the cornerstone of adjuvant 
treatment for HR+ cancers, yet only 50% of women with HR+ cancers initiated ET within a 
reasonable time period post-diagnosis. The literature suggests that even fewer adhere to ET 
for the full recommended 5 years.[17, 7] We also observed another concerning problem: 
22% of our sample did not receive any surgical intervention in the 15 months post-diagnosis. 
Although some women may have forgone these treatments for clinically valid reasons, the 
overall high rates of under-utilization of both ET and surgery may indicate that this low-
income population remains particularly underserved, despite having access to health 
insurance.
Our estimates of ET initiation were lower than those reported in other settings (e.g., older 
women in academic medical centers;[10] privately insured women;[23, 13] and New York 
Medicaid patients[12]), perhaps reflecting particular vulnerabilities of younger and 
Medicaid-insured patients in North Carolina, such as poor access to care. Our results are 
also different from a previous study conducted in NC Medicaid patients in an earlier time 
period, 1998–2002,[11] but a number of methodological differences between the two studies 
may account for the difference in findings (i.e., that study included women older than 65, 
whereas ours did not, due to our focus on understudied younger women; that study included 
all women who were HR+ or had unknown HR status and received BCS, whereas ours 
examined only HR+ women receiving any type of surgical intervention or no surgical 
intervention). Despite slight differences in methodological approach and time period of 
observation, our study and others suggest that ET initiation is substantially lower than it 
should be.
Taking ET is accompanied by many known side effects (e.g., hot flashes and other 
menopausal symptoms; joint pain) that likely influence whether women decide to initiate the 
medication.[24, 10, 15, 25, 26] Additionally, adherence to a daily medication that causes 
uncomfortable side effects to prevent recurrence—a silent health condition for which 
patients may feel they are not particularly at risk—may be difficult for many women, 
particularly those who are already socioeconomically vulnerable or have poor access to 
supportive care. As such, interventions that focus on education, outreach, and support may 
help low-income women better understand their personal risk for recurrence and make more 
evidence-informed decisions about whether and how to take ET for the recommended time 
duration.
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In our study, BCCCP enrollment was significantly associated with receipt of ET. The 
reasons for this may be multifactorial: BCCCP-enrolled women, who were previously 
uninsured and whose breast cancer was detected through free screening provided by 
BCCCP, may have been previously quite disconnected from health care services, and 
enrollment in BCCCP may empower them to become more connected to health services. In 
addition, certain health providers or systems may be more likely to facilitate BCCCP 
enrollment and may also provide better quality of care. It is possible that ‘safety net’ and 
assistance programs like BCCCP have the potential to improve quality of survivorship and 
follow-up care in particularly underserved, hard-to-reach populations. If this is true, then the 
policies and procedures associated with BCCCP should be studied in more depth to better 
understand the nature of support that is provided, as it may be leveraged further.
Several explanations may account for the fact that 22% of women in our sample did not 
undergo surgery. First and foremost, it is possible that women were lost to clinical follow-
up, but still enrolled in Medicaid. Indeed, 10% of the total study sample did not receive any 
primary therapy at all within 15 months, which may mean that these women declined or 
delayed treatment intentionally or that they were interested in receiving treatment, but were 
not able to do so due to poor access to care or ineffective navigation through the treatment 
and referrals process. This finding is consistent with other studies which have reported 
treatment disparities in lower income breast cancer populations.[27–29] It is also possible 
that treating providers made a clinical decision not to perform surgery in an otherwise 
curable patient, perhaps due to other serious co-morbid illnesses which may be more 
common among lower income patients.[30]) Lastly, women initially reported as having early 
stage disease may have been determined later to have metastatic disease, leading to other 
non-surgical treatments.
One potential implication for these findings pertains to the role of the oncologist and 
primary care provider (PCP) in managing breast cancer survivors during the 5 years they are 
supposed to be taking ET. Research shows that PCPs may be able to help coordinate breast 
cancer survivorship care.[31, 2] Given oncology specialist shortages and increasing demand 
for breast cancer follow-up care resulting from growing numbers of survivors, PCPs may be 
vital agents in helping patients seek consultation and follow-up from a medical oncologist so 
that adjuvant ET may be prescribed, if indicated.[32–34]
A number of important limitations accompany our analysis. First and foremost, we focused 
on initiation of ET as measured by prescription fills of ET in pharmacy claims data. Such 
data cannot provide information about (a) whether women actually swallowed the first pill 
after filling the prescription; or (b) whether providers wrote prescriptions for ET that were 
never filled by patients. We also were unable to measure in claims or registry data some 
important factors that may influence ET initiation, such as patient perceptions and concerns 
about taking medication every day and patient-provider communication. Given the 
observational nature of our data, we also are unable to say whether associations between 
certain independent variables such as BCCCP enrollment and ET initiation are causal. 
Second, Medicaid prescription claims data may be incomplete if women pay out of pocket 
for low-cost ET. This is more likely the case in later years, as cheaper, generic ET 
medications became available on the market and may help explain our study’s finding that 
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earlier year of diagnosis was associated with higher odds of ET receipt. Nonetheless, we 
expect that most low-income, Medicaid-insured women with pharmacy benefits would 
rather have Medicaid pay for their ET than to pay out of pocket. Third, because our analysis 
was conducted in a NC population insured by Medicaid, findings may not be generalizable 
to other states’ Medicaid programs or to other non-Medicaid populations. Nevertheless, 
results from this research may help inform other state-based and private sector initiatives in 
NC and elsewhere to improve the quality of care for breast cancer survivors. Finally, our 
small sample size prevented us from having sufficient power to detect whether important 
disparities in ET use exist by race/ethnicity, rural/urban residence, unemployment status, and 
social isolation. Nonetheless, because all women in our sample were Medicaid-insured, they 
are all vulnerable socioeconomically, and some studies suggest that socioeconomic status is 
a greater predictor of health and healthcare behavior than race and other indicators of 
vulnerability.[35, 36]
These findings suggest an urgent need for improvement. Qualitative research may help 
elucidate why women fail to initiate this important medication and how to improve ET in 
underserved populations. Interventions aimed at improving adjuvant ET initiation and 
sustaining adherence in the long-term, particularly in underserved populations like Medicaid 
patients, are necessary to address sub-optimal survivorship care and improve breast cancer 
outcomes. Policies and programs that emphasize the benefits of long-term adherence to ET 
and reduce structural barriers to care (such as lack of oncology providers who accept 
Medicaid insurance) are recommended. In turn, optimizing the delivery of ET will 
eventually lead to fewer breast cancer recurrences and improvements in mortality in 
underserved populations. 11
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Inclusion and exclusion criteria applied to identify the analytic sample
Notes: * Includes stage 0 women receiving breast conserving therapy or no surgery; ** 
Excludes women who did not receive primary therapy
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Table 1








50.0 (111) 50.0 (111)
Clinical Characteristics
NCI Combined Comorbidity Index mean (SD)† 0.27 (0.41) 0.27 (0.44)
Tumor Stage
  Stage 0 9.9 (11) 12.6 (14)
  Stage 1(reference category) 61.3 (68) 52.3 (58)
  Stage 2 28.8 (32) 35.1 (39)
Socio-demographic Characteristics
  Age mean (SD) 49.0 (8.6) 50.2 (9.1)
  Race
    White (reference category) 49.5 (55) 45.0 (50)
    Black 34.2 (38) 40.5 (45)
    Other 16.2 (18) 14.4 (16)
  Urban Residence 64.9 (72) 68.5 (76)
  Blind/Disabled classification 45.9 (51) 52.3 (58)
  BCCCP participation 30.6 (34) 11.7 (13) p<0.001
  Year of Diagnosis
    2004 15.3 (17) 9.9 (11)
    2005 27.0 (30) 24.3 (27)
    2006 25.2 (28) 27.9 (31)
    2007 (reference category) 32.4 (36) 37.8 (42)
Therapeutic Characteristics
  Chemotherapy 58.6 (65) 50.5 (56)
  Radiation 66.7 (74) 50.5 (55) p=0.01
  Surgery
    Mastectomy (reference category) 55.0 (61) 48.6 (54)
    BCS 29.7 (33) 22.5 (25)
    No Surgery 15.3 (17) 28.8 (32) p=0.01
  No Primary Treatment 4.5 (5) 16.2 (18) p=0.004
Endocrine Therapy Outcomes
  Tamoxifen only 56.8 (63) --
  Aromatase Inhibitors only 36.0 (40) --
    Anastrozole‡ 50.0 (20) --
    Letrozole‡ 32.5 (13) --
    Exemestane‡ 7.5 (3) --
  Switched Endocrine Therapy prescriptions§ 7.2 (8) --





















  Mean days to first prescription fill 267 (104) --
Notes: HR+, Hormone Receptor Positive; ET, Endocrine Therapy; SD, Standard Deviation; BCCCP, Breast and Cervical Cancer Control Program; 
BCS, Breast Conserving Surgery; NCI, National Cancer Institute; AI, Aromatase Inhibitor;
†
NCI Combined Comorbidity Index for cancer site-specific conditions in claims data (Klabunde et al, 2007);
‡
among women filling AI prescriptions;
§
women switching between any prescription class
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Table 2
Logistic Regression Estimation of Receipt of Endocrine Therapy in Primary Analytic Sample
Patient Characteristics Endocrine Therapy OR 95% CI
Clinical characteristics
  Comorbidity Score 1.042 (0.504 – 2.156)
  Tumor Stage (Stage 1 reference category)   
    Stage 0 0.869 (0.309 – 2.438)
    Stage 2 0.716 (0.370 – 1.387)
Socio-demographic
  Age 0.977 (0.939 – 1.016)
  Race (White reference category)
    Black 0.84 (0.439 – 1.609)
    Other 1.434 (0.584 – 3.518)
  Urban Residence 0.894 (0.478 – 1.673)
  Blind/Disabled classification 1.234 (0.595 – 2.557)
  BCCCP participation 3.759*** (1.666 – 8.480)
  Year of Diagnosis (2007 reference category)
    2004 2.805** (1.032 – 7.622)
    2005 2.110* (0.918 – 4.849)
    2006 1.398 (0.623 – 3.137)
Therapeutic Characteristics
  Chemotherapy 1.013 (0.497 – 2.064)
  Radiation 1.463 (0.743 – 2.880)
  Surgery (Mastectomy reference category)
    BCS 1.183 (0.481 – 2.911)
    No Surgery 0.574 (0.262 – 1.260)
Constant 1.538 (0.183 – 12.96)
Observations 222
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